Newton Fund - DEVELOPMENT OF DIFFERENTIATED PRODUCT CONCEPTS FOR INSULIN GLARGINE

牛顿基金 - 甘精胰岛素差异化产品概念的开发

• 批准号: 102725
• 金额: $ 37.8万
• 依托单位: ARECOR LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102725
• 关键词: Newton; Fund; DEVELOPMENT; DIFFERENTIATED; PRODUCT

Availability of low cost insulin products, particularly products that can be distributed and used outside the coldchain is critical to developing an effective healthcare system that can deal with the rapidly increasing incidenceof diabetes. This project will combine the expertise and technologies of Arecor and Cadila Pharmaceuticals todevelop a innovative, low cost basal insulin product that can be distributed and used outside the cold chain. Inaddition validated technology will be employed to extend the duration of action of insulin glargine withbeneficial consequences to the control of hypoglycaemia. The scope of the project will allow formulationdevelopment and optimisation, stability testing and pre-clinical development. Following successful completionof the project, the project partners will progress the asset into clinical development and commercialisation. Thefinal product, which will draw on Arecor’s proprietary formulation technologies and Cadila’s excellent trackrecord in therapeutic development and commercialisation, will represent an attractive commercial opportunityas well as having a strong positive impact on the economic development and social welfare in India.

低成本胰岛素产品的可用性，尤其是可以在冷链之外分发和使用的产品，对于开发有效的医疗保健系统至关重要，该系统可以应对糖尿病发病率的迅速增加。该项目将结合Arecor和Cadila Pharmaceuticals的专业知识和技术，可以开发一种创新的，低成本的基本胰岛素产品，可以在冷链之外分发和使用。未经验证的技术将被采用，以延长胰岛素的作用持续时间，并对控制低血糖的控制有益。该项目的范围将允许公式开发和优化，稳定性测试和临床前开发。成功完成项目后，项目合作伙伴将资产发展为临床开发和商业化。最终产品将利用Arecor的专有配方技术和Cadila的出色疗法。发展和商业化将代表一个有吸引力的商业机会，并对印度的经济发展和社会福利产生强烈的积极影响。